Cadrenal Therapeutics, Inc. Common Stock (CVKD)
Largest Insider Buys in Sector
CVKD Stock Price History Chart
CVKD Stock Performance
About Cadrenal Therapeutics, Inc. Common Stock
Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
Insider Activity of Cadrenal Therapeutics, Inc. Common Stock
Over the last 12 months, insiders at Cadrenal Therapeutics, Inc. Common Stock have bought $0 and sold $0 worth of Cadrenal Therapeutics, Inc. Common Stock stock.
On average, over the past 5 years, insiders at Cadrenal Therapeutics, Inc. Common Stock have bought $147,504 and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 2,669 shares for transaction amount of $1,842 was made by MURPHY JOHN RAYMOND (director) on 2023‑10‑05.
List of Insider Buy and Sell Transactions, Cadrenal Therapeutics, Inc. Common Stock
| 2023-10-05 | director | 2,669 0.0073% | $0.69 | $1,842 | -23.42% | |||
| 2023-10-04 | director | 17,331 0.0481% | $0.70 | $12,132 | -29.20% | |||
| 2023-09-05 | CEO and Chairman | 40,000 0.1436% | $0.90 | $36,188 | -41.76% | |||
| 2023-09-01 | CEO and Chairman | 70,000 0.2538% | $0.91 | $63,945 | -43.38% | |||
| 2023-03-16 | director | 20,000 0.1325% | $1.67 | $33,398 | -45.71% |
Insider Historical Profitability
| Pham Quang X | CEO and Chairman | 3410000 205.5739% | $14.77 | 2 | 0 | <0.0001% |
| MURPHY JOHN RAYMOND | director | 614792 37.0631% | $14.77 | 3 | 0 | <0.0001% |